Filter Results:
(146)
Show Results For
- All HBS Web
(1,092)
- Faculty Publications (146)
Show Results For
- All HBS Web
(1,092)
- Faculty Publications (146)
Page 1 of 146
Results →
- August 2024
- Case
Pioneering Pain Management: CWC Alliance Combats the Opioid Epidemic
By: Susanna Gallani, Karen L. Sedatole and Sarah Mehta
Set in March 2024, this case is about CWC Alliance (CWC), a nonprofit working to prevent opioid addiction in the U.S. Founder Cammie Wolf Rice launched CWC in 2018 after her son, Christopher Wolf, died of a heroin overdose. Wolf’s dependence on opioids stemmed from a... View Details
Keywords: Health; Innovation and Invention; Jobs and Positions; Social Enterprise; Strategy; Health Industry; United States; Georgia (state, US); Atlanta
Gallani, Susanna, Karen L. Sedatole, and Sarah Mehta. "Pioneering Pain Management: CWC Alliance Combats the Opioid Epidemic." Harvard Business School Case 125-012, August 2024.
- August 2024
- Article
How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
Keywords: Prescription Drugs; Coupons; Impact; Health Care and Treatment; Markets; Price; Spending; Pharmaceutical Industry; United States
Dafny, Leemore S., Kate Ho, and Edward Kong. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?" American Economic Journal: Economic Policy 16, no. 3 (August 2024): 314–346.
- May 2024
- Case
Choosing the Course of Passion: Brooke Boyarsky Pratt at knownwell
By: Jon M. Jachimowicz and Alexis Lefort
Brooke Boyarsky Pratt (HBS ’13) enjoyed considerable success in her early career, quickly climbing the ranks to associate partner at McKinsey, and later becoming an executive vice president at Berkadia, a Berkshire Hathaway portfolio company. Throughout these years,... View Details
Keywords: Passion; Career; Career Planning; Purpose; Personal Development and Career; Mission and Purpose; Identity; Business Startups; Health Care and Treatment; Health Disorders; Growth and Development Strategy; Market Entry and Exit; Health Industry; United States
Jachimowicz, Jon M., and Alexis Lefort. "Choosing the Course of Passion: Brooke Boyarsky Pratt at knownwell." Harvard Business School Case 424-040, May 2024.
- May 2024
- Technical Note
Health Care Payment in the United States
By: Robert S. Huckman, Jeff Charca and Craig Garthwaite
This document provides an overview of how various actors (e.g., physicians, hospitals, and other health care providers) are paid in the United States health care system. It is particularly focused on features of the payment system that contribute to strategic decisions... View Details
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Health Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
Badaracco, Joseph L., Tom Quinn, and John Schultz. "Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs." Harvard Business School Case 324-114, April 2024. (Revised July 2024.)
- January 19, 2024
- Article
Value-Based Health Care Can Transform the Treatment of Patients with Substance Use Disorder
By: Robert S. Kaplan and Sarah E. Wakeman
U.S. overdose deaths currently exceed 100,000 per year. New facilities, known as bridge clinics, are broadening access to high-quality care by offering outpatient substance use disorder (SUD) treatment with few access barriers. But many of the critical services offered... View Details
Kaplan, Robert S., and Sarah E. Wakeman. "Value-Based Health Care Can Transform the Treatment of Patients with Substance Use Disorder." Health Affairs Forefront (January 19, 2024).
- October 2023
- Supplement
Hey Jane: Background on Abortion in the U.S.
By: Rembrand Koning, Geraldine Pena-Galea and Sarah Mehta
Koning, Rembrand, Geraldine Pena-Galea, and Sarah Mehta. "Hey Jane: Background on Abortion in the U.S." Harvard Business School Supplement 724-390, October 2023.
- October 2023
- Case
Hey Jane: Delivering Abortion Pills to the Doorstep
By: Rembrand Koning, Geraldine Pena-Galea and Sarah Mehta
This case tells the story of Hey Jane, a telehealth clinic founded in 2020 that provides virtual medication abortion services to eligible patients in nine U.S. states. By January 2023, the company had served more than 20,000 patients and raised nearly $10 million in... View Details
Keywords: Operations; Business Startups; Health Care and Treatment; Growth and Development Strategy; Health Industry; Technology Industry; United States
Koning, Rembrand, Geraldine Pena-Galea, and Sarah Mehta. "Hey Jane: Delivering Abortion Pills to the Doorstep." Harvard Business School Case 724-408, October 2023.
- October 2023
- Article
What Does the Inflation Reduction Act Mean for Patients and Physicians?
By: Amitabh Chandra and Benedic Ippolito
The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed their effect on physicians and patients via their effect on payers. Reducing patients’ costs... View Details
Chandra, Amitabh, and Benedic Ippolito. "What Does the Inflation Reduction Act Mean for Patients and Physicians?" NEJM Catalyst Innovations in Care Delivery 4, no. 10 (October 2023).
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- May 2023
- Article
Decarbonizing Health Care: Engaging Leaders in Change
By: Vivian S. Lee, Kathy Gerwig, Emily Hough, Kedar Mate, Robert Biggio and Robert S. Kaplan
Health care leaders are often surprised to learn that their operations contribute
significantly to a warming climate. In addition to their roles as responders to and victims
of extreme weather events, health care organizations have an obligation to reduce... View Details
Keywords: Health Care; Decarbonization; Carbon Emissions; Net-zero Emissions; Climate Change; Health Care and Treatment; Health Industry
Lee, Vivian S., Kathy Gerwig, Emily Hough, Kedar Mate, Robert Biggio, and Robert S. Kaplan. "Decarbonizing Health Care: Engaging Leaders in Change." NEJM Catalyst Innovations in Care Delivery 4, no. 5 (May 2023).
- March 2023 (Revised March 2024)
- Case
The Purdue Pharma Bankruptcy: Settling the Opioid Crisis
By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
- February 2023
- Article
A Different Framework to Achieve Universal Coverage in the U.S.
By: Katherine Baicker, Amitabh Chandra and Mark Shepard
This JAMA Forum discusses alternative ways to achieve universal coverage in the US such as administrative simplification in the Affordable Care Act plans to increase enrollment, having a basic policy that would be available to everyone, and options for supplemental... View Details
Baicker, Katherine, Amitabh Chandra, and Mark Shepard. "A Different Framework to Achieve Universal Coverage in the U.S." e230187. JAMA Health Forum 4, no. 2 (February 2023).
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- January 2023
- Teaching Note
Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care
By: Robert S. Kaplan
This Teaching Note was prepared to aid classroom instructors in the use of "Brigham and Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care," HBS Case No. 122-010. View Details
- September 2022
- Technical Note
Addressing Social Determinants of Health in the American Landscape
By: Susanna Gallani and Jacob Riegler
Social determinants of health (SDOH) have gained significant attention in recent years. A growing body of research shows that a person’s health is influenced by a large number of non-genetic factors, most of which operate outside the realm of health care and are... View Details
Keywords: Socioeconomic Determinants Of Health; Social Determinants Of Health; Population Health; Health; Health Care and Treatment; Social Issues; Health Industry; Insurance Industry; Medical Devices and Supplies Industry; United States
Gallani, Susanna, and Jacob Riegler. "Addressing Social Determinants of Health in the American Landscape." Harvard Business School Technical Note 123-023, September 2022.
- August 3, 2022
- Article
How Will Amazon Approach U.S. Primary Care?
By: Robert S. Huckman and Bradley Staats
Amazon has a playbook for reinventing businesses that it enters. It includes simplifying processes, experimenting to determine which new approaches work best, and continuously recombining its existing assets to come up with a better way to do things. It is likely to... View Details
Keywords: Amazon; Health Care; Technology; Primary Care; Health Care and Treatment; Information Infrastructure; Health Industry; Technology Industry; United States
Huckman, Robert S., and Bradley Staats. "How Will Amazon Approach U.S. Primary Care?" Harvard Business Review (website) (August 3, 2022).